Abstract
(age < 65 years), and 9 (40.9%) were elderly (age � 65 years). Seven patients (31.8%) were treated with cetuximab, 6 (27.3%) with panitunumab, and 9 (40.9%) with erlotinib. One patient (4.5%) was treated in first-line therapy, 8 patients (36.4%) in second-line, 11 (50.0%) in third-line, and 2 (9.1%) in fourth-line. Cetuximab was associatedwith5-fluorouracil,folinicacid,andirinotecan(FOLFIRI) in 1patient (14.3%) and with irinotecan in 6 patients (85.7%),while panitunumab was associated with 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX) in 1 patient (16.7%) and alone in the other 5
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
